Access to investigational drugs has been a controversial topic during the COVID19 pandemic: what is the level of evidence required? How do we evaluate individual access requests, particularly from public figures such as outgoing Presidents? How does providing access change the ability to acquire fundamental information about these products? In May 2018, the Right to Try Act was signed into law, creating a new pathway for patients with life-threatening conditions to access investigational products prior to FDA approval. Prior to the federal law, more than half of states had passed their own versions of right to try. Two expert panelists will consider the scientific, legal, and ethical issues relating to access to investigational treatments and how Right to Try laws change the landscape for the future.
Discussants:
George Q. Daley, MD, PhD
Dean of the Faculty of Medicine
Harvard Medical School
Alison Bateman-House, MPH, PhD
Assistant Professor
Department of Population Health
NYU Grossman School of Medicine
Moderator:
Insoo Hyun, PhD
Director of Research Ethics
Center for Bioethics
Harvard Medical School
Professor of Bioethics
Case Western Reserve University
School of Medicine
LOCATION:Virtual, via Zoom - register to receive the link via email STATUS:CONFIRMED DTSTART:20201202T173000Z DTEND:20201202T173000Z END:VEVENT END:VCALENDAR